Skip to Content

Eteplirsen Dosage

Applies to the following strength(s): 50 mg/mL

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Muscular Dystrophy

30 mg/kg IV over 35 to 60 minutes once a week

Comments:
-Administer missed doses as soon as possible after the scheduled time.

Use: For the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping

Usual Pediatric Dose for Muscular Dystrophy

30 mg/kg IV over 35 to 60 minutes once a week

Comments:
-Administer missed doses as soon as possible after the scheduled time.

Use: For the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-A topical anesthetic may be applied to the infusion site prior to administration.
-Flush the IV line with 0.9% sodium chloride prior to and after the infusion.
-Infuse the solution over 35 to 60 minutes.

Storage requirements:
-The manufacturer product information should be consulted.

Reconstitution/preparation techniques:
-The manufacturer product information should be consulted.

IV compatibility:
-Other medications should not be mixed or infused concomitantly with this drug via the same IV line.

General:
-This drug is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with this drug.
-Clinical benefit of this drug has not been established.
-Continued approval for DMD may be contingent upon verification of clinical benefit in confirmatory trials.

Hide